Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
841-860 of 991 trials

Alcohol Use Disorder: Sunobinop Study

We are testing whether Sunobinop can help reduce heavy drinking days for individuals with alcohol use disorder. This study aims to understand its effects on overall alcohol consumption and cravings.

Alcohol Use Disorder≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPsychiatry

Multiple Myeloma: ABBV-453 Treatment Study

We are studying the safety and effects of ABBV-453, alone or with other treatments, for adults with multiple myeloma. This research aims to understand how well it works and how it is tolerated by patients.

Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Solid Tumors: GSK5733584 with Anti-Cancer Therapies

We are studying a new drug, GSK5733584, combined with other cancer treatments for patients with advanced solid tumors. The trial aims to evaluate its safety and how well it may work in this setting.

Gynecological TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Multiple System Atrophy: Lu AF82422 Study

We are testing the medication Lu AF82422 to see if it can slow disease progression in people with Multiple System Atrophy. The study will also look at its effects on overall health and quality of life.

Multiple System Atrophy1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Bipolar Depression: Lithium vs. Cariprazine

We are comparing the effectiveness of lithium and cariprazine for treating acute depressive episodes in people with bipolar disorder. The goal is to find out which medication may lead to better improvements in mood.

Depressive Episode in Bipolar Disorder≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Sarcopenia Treatment: Nandrolone and Therapy

We are studying whether nandrolone, along with physiotherapy and diet, can improve muscle strength in people with sarcopenia. This research aims to find effective treatments for muscle loss.

Sarcopenia≤3 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Ovarian Cancer: Mirvetuximab Soravtansine Study

We are evaluating different dosing schedules of mirvetuximab soravtansine for patients with advanced ovarian, peritoneal, or fallopian tube cancers. This study aims to find the safest and most effective way to administer the treatment.

Advanced Ovarian and Fallopian Tube Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Advanced Ovarian Cancer: TORL-1-23 Treatment Study

We are studying the effectiveness of TORL-1-23 in women with advanced platinum-resistant ovarian cancer that expresses Claudin 6. This research aims to find new treatment options for this challenging condition.

Peritoneal CancerOvarian CancerFallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Colorectal Cancer: MK-1084 Treatment Study

We are testing a new treatment combining MK-1084, cetuximab, and chemotherapy for patients with advanced colorectal cancer. The goal is to see if this combination is safer and more effective than standard treatments.

Metastatic Colorectal CancerKRAS Mutation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Higher Risk Myelodysplastic Syndrome: Lisaftoclax with Azacitidine

We are studying whether the combination of Lisaftoclax and azacitidine is more effective than a placebo with azacitidine for adults newly diagnosed with higher risk myelodysplastic syndrome. The trial will also assess safety and patient-reported outcomes.

Higher Risk Myelodysplastic SyndromeConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Juvenile Psoriatic Arthritis: Deucravacitinib Study

We are testing a new medication, deucravacitinib, in children and teens aged 5 to 18 with Juvenile Psoriatic Arthritis. The study aims to see if it works better than a placebo and to ensure it is safe and easy to take.

Systemic Juvenile Idiopathic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsRheumatology

BOTOX® for Preventing Pancreatic Fistula After Surgery

We are studying whether BOTOX® injections before surgery can help prevent complications in patients undergoing distal pancreatectomy. This trial will assess the safety and effectiveness of this approach.

Postoperative Pancreatic Fistulas≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

T-Guard for Early Diffuse Cutaneous Systemic Sclerosis

We are studying the safety and effectiveness of T-Guard in patients with early diffuse cutaneous systemic sclerosis. This trial will help us understand how well the treatment works and how it is processed in the body.

Diffuse Systemic Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyInternal MedicineRheumatology

Psoriatic Arthritis: JNJ-77242113 Study

We are testing a new medication for people with active psoriatic arthritis who have used other biologic treatments. The study aims to see if it can reduce symptoms better than a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Myeloma Treatment: Elranatamab vs. Daratumumab

We are studying whether elranatamab combined with lenalidomide helps patients with newly diagnosed myeloma maintain remission better than daratumumab with lenalidomide after a transplant. This trial will also assess safety and quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

TOASST Study: Comparing Steroid Withdrawal Methods

We are studying whether stopping glucocorticoids suddenly is as safe as tapering them for patients with inflammatory disorders. This research may help improve treatment strategies and patient outcomes.

Inflammatory or Autoimmune Disorders>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Rheumatoid Arthritis: CIT-013 Study

We are investigating a new medication, CIT-013, for people with moderately active rheumatoid arthritis. The study aims to see if it helps reduce disease activity and to understand its safety.

Moderately Active Rheumatoid Arthritis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Scarred Vocal Folds: Autologous Fat Injection Study

We are investigating whether an injection of fat-derived cells can improve voice quality in individuals with scarred vocal folds. This study compares the treatment to a placebo to assess its effectiveness and safety.

Scarred Vocal Folds>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: BMS-986365 vs. Standard Treatment

We are comparing a new medication, BMS-986365, to standard treatments for men with metastatic castration-resistant prostate cancer. The study aims to see if the new drug can better delay disease progression and improve overall health.

Metastatic Castration-resistant Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology